Companies › Cerenome
1 active drug program in 5 registered trials: 5 Phase 1; Oncology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rhenium-186 Nanoliposome (186RNL) 186Re-BMEDA-chelated radionuclide encapsulated in liposomes for convection-enhanced delive | – | Phase 1 | Leptomeningeal Metastasis; Glioma; Ependymoma | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05034497 | Rhenium-186 Nanoliposome (186RNL) | Phase 1 | Leptomeningeal Metastasis | Oncology | Oct 2026 |
| NCT01906385 | Rhenium-186 Nanoliposome (186RNL) | Phase 1 | Glioma | Oncology | Apr 2027 |
| NCT07098806 | Rhenium-186 Nanoliposome (186RNL) | Phase 1 | Leptomeningeal Metastasis | Oncology | Jul 2027 |
| NCT05460507 | Rhenium-186 Nanoliposome (186RNL) | Phase 1 | Glioma | Oncology | Mar 2028 |
| NCT07061626 | Rhenium-186 Nanoliposome (186RNL) | Phase 1 | Ependymoma | Oncology | Mar 2028 |
Cash and short-term investments of $9m on 2026-06-30; operating cash outflow about $27m a year; runway about 4 months at that burn, to Oct 2026
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.